Bildkälla: Stockfoto

Egetis Therapeutics: Q2’21: Emcitate A Bright Spot - Redeye

Redeye believes the Q2 report supports our view that flagship project Emcitate is on track.

Redeye believes the Q2 report supports our view that flagship project Emcitate is on track.
Börsvärldens nyhetsbrev
ANNONSER